Sugranes Rosa
Known title: DirectorCIK: 0001364133
Sugranes Rosa's purchase track record
Sugranes Rosa has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/10/2023 | FHN | $20K | +33.9% | +15.0% | +5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| FHN | ▲ Buy | Grant | 9,414 | $0 | 4/29/2024 | View on chart |
| FHN | ▲ Buy | Open Market | 1,948 | $20K | 5/10/2023 | View on chart |
| FHN | ▲ Buy | Grant | 6,955 | $0 | 5/2/2023 | View on chart |
| FHN | ▲ Buy | Grant | 5,391 | $0 | 5/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Evercore and Wells Fargo Lower FHN Price Targets to $25
Evercore ISI and Wells Fargo recently lowered their price targets for First Horizon to $25, citing concerns about the bank's net interest income in a rising rate environment. These updates align with the stock trading near its 52-week low, reflecting cautious sentiment among analysts. The average analyst target remains at $27.69, but the recent cuts indicate a more conservative outlook for the near term.
Evercore and Wells Fargo Lower FHN Price Targets to $25. Evercore ISI and Wells Fargo recently lowered their price targets for First Horizon to $25, citing concerns about the bank's net interest income in a rising rate environment. These updates align with the stock trading near its 52-week low, reflecting cautious sentiment among analysts. The average analyst target remains at $27.69, but the recent cuts indicate a more conservative outlook for the near term.